Crewe Advisors’s Amicus Therapeutics FOLD Stock Holding History

Crewe Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-610	Closed	-$6.76K	–	932
2023 Q1	$6.76K	Hold	610	–	–	﹤0.01%	599
2022 Q4	$7.45K	Hold	610	–	–	﹤0.01%	605
2022 Q3	$6K	Hold	610	–	–	﹤0.01%	795
2022 Q2	$7K	Buy	+610	New	+$5.02K	﹤0.01%	686

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Crewe Advisors's FOLD Position: Q2 2023 in Review

Crewe Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 610 shares — an estimated $6.76K sold.

Crewe Advisors first reported a position in FOLD in Q2 2022 and held it in 4 quarters. The position peaked at $7.45K in Q4 2022. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

Crewe Advisors reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 610 Amicus Therapeutics shares in Q2 2023, an estimated $6.76K.
Crewe Advisors first reported a position in Amicus Therapeutics in Q2 2022 and held it in 4 quarters.
Crewe Advisors's Amicus Therapeutics position peaked at $7.45K in Q4 2022.
216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.